Defining High-Risk Precursor Signaling to Advance Breast Cancer Risk Assessment and Prevention
Abstract
Making a major impact on the incidence and lethality of breast cancer will require a detailed understanding of the earliest tissue changes that ultimately drive the process of breast cancer development. There is no substitute for the ability to define and understand the early, pre-malignant changes as they occur in women who are breast cancer predisposed. One group of women at high breast cancer risk (up to 80 percent lifetime breast cancer risk) are those who have inherited mutations in the BRCA1 and BRCA2 genes. Currently, the only way these women can eliminate their risk is to undergo bilateral mastectomy before developing cancer. We have established an IRB-approved protocol that allows us to collect and analyze a portion of this tissue.
Document Details
- Document Type
- Technical Report
- Publication Date
- Mar 01, 2017
- Accession Number
- AD1046829
Entities
People
- Leif W Ellisen
Organizations
- Massachusetts General Hospital